Betacoronavirus RNA vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Sunny Himansu
Life of this patent
Estimating the term…
Abstract
The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to non-self-replicating RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Claims20
A betacoronavirus vaccine for human subjects comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle, wherein the mRNA comprises an open reading frame encoding a full-length betacoronavirus (BetaCoV) S protein, wherein the open reading frame comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine, wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid, and wherein the vaccine is formulated for intramuscular injection at a dose that comprises 20-50 μg of the mRNA and a ratio of lipid to mRNA of from 5:1 to 30:1, and has an efficacy against betacoronavirus infection in human subjects of at least 90%.
A betacoronavirus vaccine for human subjects comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle, wherein the mRNA comprises an open reading frame encoding a full-length betacoronavirus (BetaCoV) S protein, wherein the open reading frame comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine, wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid, and wherein the vaccine is formulated for intramuscular injection at a dose that comprises 20-50 μg of the mRNA, and has an efficacy against betacoronavirus infection in human subjects of at least 90%.
Dependencies are inferred from the claim text.